Company Overview - DBV Technologies is a late-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions with significant unmet medical needs [3]. - The company is headquartered in Châtillon, France, with North American operations in Warren, NJ [4]. - DBV Technologies' ordinary shares are traded on Euronext Paris and its American Depositary Shares (ADSs) are traded on the Nasdaq Capital Market [4]. Product Development - The company is investigating the use of its proprietary VIASKIN patch technology to address food allergies, which are caused by hypersensitive immune reactions [3]. - VIASKIN patch utilizes epicutaneous immunotherapy (EPIT) to introduce microgram amounts of biologically active compounds to the immune system through intact skin, aiming to modify the underlying allergy by re-educating the immune system [3]. - Ongoing clinical trials include the VIASKIN Peanut program targeting peanut allergic toddlers (1-3 years) and children (4-7 years) [3]. Upcoming Events - DBV Technologies will participate in the Citizens Life Sciences Conference on March 10, 2026, featuring a fireside chat at 1:40 PM ET [1]. - The company will also attend the Leerink Partners Global Healthcare Conference on March 11, 2026, with a format of one-on-one meetings [2].

Core Insights - DBV Technologies has filed its 2025 Half-Year Report with the French market authority, AMF, for the period ending June 30, 2025 [1] - The company is focused on developing treatment options for food allergies and other immunologic conditions, utilizing its proprietary VIASKIN patch technology [2][3] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company headquartered in Châtillon, France, with operations in North America [3] - The company is dedicated to addressing significant unmet medical needs related to food allergies, particularly through epicutaneous immunotherapy (EPIT) [2] - The VIASKIN patch aims to desensitize individuals to allergens by introducing microgram amounts of biologically active compounds through intact skin [2] Clinical Focus - DBV Technologies is currently conducting clinical trials for its VIASKIN Peanut product, targeting peanut allergic toddlers aged 1 to 3 years and children aged 4 to 7 years [2]